KROS vs UNH

Keros Therapeutics retains significant 10x growth potential within 3-5 years due to its deep pipeline targeting large unmet medical needs via the TGF-beta pathway. The Takeda licensing deal in FY25 provided substantial revenue and validated its platform. Key near-term catalysts remain the Phase 2/3 data readouts for KER-050 and KER-012, backed by a cash runway into H1 2028. However, recent Q4 2025...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...